Calcified aortic valve disease is a common cardiovascular disease. With the aging of the population, it becomes a major medical burden. Valve replacement is the main treatment of the disease, but the elderly group has a high risk of operation and a high incidence of complications. There are still no drugs to prevent or slow the progression of the disease. It has been found that lipoprotein (a) plays a key role in the pathophysiology of valvular calcification. The increase of lipoprotein (a) level is an important risk factor for calcified aortic valve disease and can increase the risk of aortic stenosis. This article reviews the pathological mechanism of lipoprotein (a) involved in calcified aortic valve disease, and the therapy of calcified aortic valve disease.